Skip to main content

mHeath based Diabetes Management in India - Remote monitoring Tools


In the past we have read a lot of research projects that determine the outcomes based overview of Diabetes management and the use of remote monitoring tools. We have spoken to Doctors,  technologists as well as equipment manufacturers and all of these available tools represent a breakthrough for clinician/patient communication to enhance disease management and improve health outcomes.

However, for India we were yet to find out the drivers, challenges, consumer behaviour, expected adoption level and value add to the end users. Here is a recent study undertaken by HealthCursor Consulting Group India to understand the DM market better.


SURVEY questionnaire:

1. If you are given a Glucometer (blood sugar check machine) for free, will you check your blood sugar daily ?
1)      Yes
2)      No


2. Your mobile phone will automatically send this data to your Doctor. Your Doctor will then SMS, EMAIL or call you if your sugar is not in control. How much you will you easily pay for this service? (Note: the doctor will not disturb you in case of normal readings.)
1)      Rs 1000-2000/month
2)      Rs 500-900/month
3)      Rs 100-400/month



3. Will you feel more comfortable if you do not have to do your blood sugar monitoring yourself but a nurse sitting in a nearby chemist store/pharmacy does it for you? In this case you will have to step out of your house but will this give you more confidence?
1)      Yes, I will feel better if a nurse does that and I don't mind driving to the chemist store.
2)      No, I would like to do it at home myself


4. Are you using a Glucometer already? Would you mind buying a new Glucometer if that connects with your phone and transfers your data automatically to the doctor?
1)      Yes, I have a Glucometer and Yes, I will buy a new one if it is the same price as my old one but has advance features like what is mentioned above.
2)      Yes, I have a Glucometer and No, I don't want a new Glucometer.
3)      No, I don't have a Glucometer but Yes, I will buy a new one if it is the same price as the one available in the market but has advance features like what is mentioned above
4)      No, I don't have a Glucometer but I will only buy known conventional brands Glucometer and will not trust any advance ones.



5. What all a Diabetic should invest in?
1)      Glucometer
2)      Glucometer, Doctor Consultation
3)      Glucometer, Doctor Consultation, Daily Glucose monitoring and advice
4)      Glucometer, Doctor Consultation,Daily Glucose monitoring and advice, Diagnostic checkups
5)      Glucometer, Doctor Consultation, Daily Glucose monitoring and advice, Diagnostic checkups, Diet plan, Exercise plan, Lifestyle and wellness plan


SAMPLE: Volunteers from the following companies participated in this survey.



Popular posts from this blog

Artificial Intelligence Policy and Governance in HEALTHCARE

  Artificial Intelligence has become the new frontier for digital transformation. Several  #digitalhealth  businesses of today rely on Machine Learning,  #AI  and other such technologies to make healthcare delivery more efficient and comprehensive. However, the efficient and responsible use of AI tools is an ongoing discussion and would mean culture, data management, technology shifts in the industry, and required up-grading and training professionals for better coordination. Hence, with the growing market potential and interest in AI, it is imperative to develop a thoughtthrough regulatory and legal framework on the adoption and use of AI. I have set forward a hypotheses to design a policy framework for AI technologies in my paper- "𝐀𝐫𝐭𝐢𝐟𝐢𝐜𝐢𝐚𝐥 𝐈𝐧𝐭𝐞𝐥𝐥𝐢𝐠𝐞𝐧𝐜𝐞 𝐢𝐧 𝐇𝐞𝐚𝐥𝐭𝐡 𝐏𝐨𝐥𝐢𝐜𝐲 – 𝐀 𝐆𝐥𝐨𝐛𝐚𝐥 𝐏𝐞𝐫𝐬𝐩𝐞𝐜𝐭𝐢𝐯𝐞" last year https://lnkd.in/emi3XWwa cited further by "𝐓𝐡𝐞 𝐐𝐮𝐚𝐧𝐝𝐚𝐫𝐲 𝐢𝐧 𝐃𝐚𝐭𝐚 𝐏𝐫𝐨𝐭𝐞𝐜𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐑

Artificial intelligence and Technology for Dentistry

Have you heard of this company  ORCA Dental AI ? ORCA combines clinical expertise with machine learning and AI technologies to create diagnostic reports, treatment plan suggestions and smart clinical predictions. Good to learn about these innovations that benefit every stakeholder in the value chain. Recently,  VideaHealth  raised $20M to Expand AI-Based Diagnostics led by Spark Capital including existing investors Zetta Venture Partners. Among its many benefits to dentists and patients are: – A 31% increase in diagnosis rate for cavities and 26% increase in treatment plan value; – An increase in case acceptance by patients due to second opinions; – Automated workflows accelerate treatment planning and charting; Another company touting AI-powered dental care and practice management is  Overjet , which announced a $42.5 million Series B funding round in December months after it had scored $27 million in Series A funding.  Pearl  provides AI for dental images to assist in diagnosis. It l

Big Data Analytics- The Microscope and Telescope for Pharma/CRO

This article is produced in consultation with Industry experts, and KOLs in India and across the world and especially highlights how “Predictive Analytics algorithms” are poised to provide Useful Analytics to the Pharma industry.   In today’s highly competitive market, it is extremely important for contract research and manufacturers to have access to information that allows them to target the specific segments of the pharmaceutical and biotechnology industry that are looking to outsource the particular services they provide.  Understanding shifts in annual outsourcing budgets and spending can help CROs and CMOs to better position themselves for capturing business, particularly at a time when many – if not all – pharma and biotech companies are looking to cut costs and streamline operations.  As per a recent report by NiceInsights, Analytical Services, Clinical Research, and Clinical Monitoring will be the most demanded services over the next 12 to 18 months. For CROs and CMOs looki